ArticleDrug target insights2014
Febuxostat for hyperuricemia in patients with advanced chronic kidney disease.
Article in Drug target insights, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Systemic Redox Imbalance in Chronic Kidney Disease: A Systematic Review.Oxidative medicine and cellular longevity · 2016Pooled it
- Effect of febuxostat on oxidative stress in hemodialysis patients with endothelial dysfunction: a randomized, placebo-controlled, double-blinded study.International urology and nephrology · 2019Trial
- Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients.Renal failure · 2019Observational
- Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.Arthritis research & therapy · 2019Article
- The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model.International journal of molecular sciences · 2018Article
- Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: A 6-months open-label, randomized controlled trial.EXCLI journal · 2018Article
- Endothelin-1, α-Klotho, 25(OH) Vit D levels and severity of disease in scleroderma patients.Rheumatology international · 2017Article
- Management of Gout and Hyperuricemia in CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017Article
- Febuxostat-induced agranulocytosis in an end-stage renal disease patient: A case report.Medicine · 2017Article
- Oxidative stress and autophagy: crucial modulators of kidney injury.Redox biology · 2015Review
- Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients.Journal of pharmaceutical health care and sciences · 2015Article
- Association between Serum Soluble Klotho Levels and Mortality in Chronic Hemodialysis Patients.International journal of endocrinology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Febuxostat is a nonpurine xanthine oxidase (XO) inhibitor, which recently received marketing approval. However, information regarding the experience with this agent among advanced chronic kidney disease (CKD) patients is limited. In the current study, we investigated the effects of oral febuxostat in patients with advanced CKD with asymptomatic hyperuricemia. We demonstrated, for the first time, that not only the serum levels of uric acid (UA) but also those of 8-hydroxydeoxyguanosine, an oxidative stress marker, were significantly reduced after six months of febuxostat treatment, with no adverse events. These results encouraged us to pursue further investigations regarding the clinical impact of lowering the serum UA levels with febuxostat in advanced CKD patients in terms of concomitantly reducing oxidative stress via the blockade of XO. More detailed studies with a larger number of subjects and assessments of the effects of multiple factors affecting hyperuricemia, such as age, sex, and dietary habits, would shed light on the therapeutic challenges of treating asymptomatic hyperuricemia in patients with various stages of CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.